RT Journal
A1 Kuehn BM
T1 GRoups propose plan to accredit controversial stem cell therapy clinics
JF JAMA
JO JAMA
YR 2012
FD August 8
VO 308
IS 6
SP 553
OP 555
DO 10.1001/jama.2012.7959
UL http://dx.doi.org/10.1001/jama.2012.7959
AB 
The proliferation of clinics offering stem cell treatments for dozens of conditions, ranging from autism to chronic obstructive pulmonary disease, has raised concerns among stem cell researchers, ethicists, and the US Food and Drug Administration (FDA). Most such clinics operate outside the United States, so they do not need FDA permission to conduct clinical trials involving stem cell treatments or to market stem cell treatments to patients, but many of the clinics recruit patients from the United States.